| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
14,410,000 |
| Market
Cap: |
4.80(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3333 - $0.3333 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,262 |
| Total Buy Value |
$0 |
$0 |
$0 |
$197,404 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Love Ted W |
President and C.E.O. |
• • – |
2005-05-31 |
4 |
A |
$6.30 |
$14,981 |
D/D |
2,378 |
2,378 |
|
- |
|
| Levy Michael D |
Sr. VP Research & Development |
• – – |
2005-05-12 |
4 |
B |
$6.31 |
$56,790 |
D/D |
9,000 |
9,000 |
2.74 |
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2005-02-28 |
4 |
A |
$6.60 |
$1,049 |
D/D |
159 |
159 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2005-02-23 |
4 |
B |
$7.51 |
$11,265 |
D/D |
1,500 |
1,879 |
2.74 |
- |
|
| Rathmann George B |
Director |
– • – |
2004-12-29 |
4 |
GD |
$10.14 |
$445,940 |
I/I |
44,000 |
903,788 |
|
- |
|
| Titus Gary |
VP Finance, Chief Acct.Officer |
• – – |
2004-11-30 |
4 |
A |
$7.69 |
$1,046 |
D/D |
136 |
379 |
|
- |
|
| Love Ted W |
President and C.E.O. |
• • – |
2004-08-31 |
4 |
A |
$7.57 |
$2,733 |
D/D |
361 |
361 |
|
- |
|
| Credit Suisse First Boston |
See Remarks |
– – – |
2004-07-30 |
4 |
OE |
$4.98 |
$1,199,393 |
I/I |
240,842 |
7,230 |
|
- |
|
| Titus Gary |
V.P. and Chief Acctg OfficerOf |
• – – |
2004-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
243 |
|
- |
|
| Love Ted W |
President and C.E.O. |
• • – |
2004-05-28 |
4 |
A |
$7.40 |
$7,393 |
D/D |
999 |
999 |
|
- |
|
| Love Ted W |
President and C.E.O. |
• • – |
2004-02-27 |
4 |
A |
$10.45 |
$7,346 |
D/D |
703 |
703 |
|
- |
|
| Zubrow Barry L |
Director |
– • – |
2004-02-20 |
4 |
B |
$4.65 |
$232,500 |
I/I |
50,000 |
50,000 |
2.1 |
- |
|
| Pendergast Mary K |
Director |
– • – |
2003-12-22 |
4 |
A |
$3.16 |
$6,330 |
D/D |
2,000 |
2,000 |
|
- |
|
| Credit Suisse First Boston |
See note (1) |
– – – |
2003-12-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
5,759,875 |
|
- |
|
| Chambon Philippe |
Director |
– • – |
2003-12-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,000,000) |
5,759,875 |
|
- |
|
240 Records found
|
|
Page 10 of 10 |
|
|
